Clinically approved combination immunotherapy: Current status, limitations, and future perspective

Immune-checkpoint inhibitor-based combination immunotherapy has become a first-line treatment for several major types of cancer including hepatocellular carcinoma (HCC), renal cell carcinoma, lung cancer, cervical cancer, and gastric cancer. Combination immunotherapy counters several immunosuppressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Ligong, Zhan, Meixiao, Li, Xian-Yang, Zhang, Hui, Dauphars, Danielle J., Jiang, Jun, Yin, Hua, Li, Shi-You, Luo, Sheng, Li, Yong, He, You-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167882/
https://www.ncbi.nlm.nih.gov/pubmed/35676925
http://dx.doi.org/10.1016/j.crimmu.2022.05.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167882/
https://www.ncbi.nlm.nih.gov/pubmed/35676925
http://dx.doi.org/10.1016/j.crimmu.2022.05.003

Ejemplares similares